Breakout Opportunity in the Biotechnology Sector - Exelixis is Market Leader in Kidney Cancer with a P/E of 14.5

The biotech heavyweight Biogen reported better-than-expected numbers today. The stock is up more than 2% and could draw more focus to the biotechnology sector. We anticipate AI-driven innovation growth in this area. Recently, financing conditions have already improved. Traders need to be aware of the profitable stocks at 52-week highs. These include Exelixis , and a new breakout is forthcoming! Cancer specialist with a 47% market share Exelixis develops and markets cancer medications. They collaborate with Ipsen and Takeda. The key revenue driver...